The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas
Open accessAbstract
In the US, approximately 850–900 children are diagnosed each year with soft tissue sarcomas (STS). Key findings from recent Children's Oncology Group (COG) clinical trials include safe reduction in therapy for low risk rhabdomyosarcoma (RMS), validation of FOXO1 fusion as a prognostic factor, a modest improvement in outcome for high‐risk RMS, and a biologically designed non‐cytotoxic therapy for pediatric desmoid tumor. Planned Phase 2 trials include targeted agents for VEGF/PDGF, mTOR, and IGF‐1R for children with RMS and VEGF for children with non‐RMS STS (NRSTS). For RMS, COG Phase 3 trials potentially will explore VEGF/mTOR inhibition or chemotherapy interval compression. For NRSTS, a COG Phase 3 trial will explore VEGF inhibition. Pediatr Blood Cancer 2013; 60: 1001–1008. © 2012 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Outcomes for children and adolescents with cancer: challenges for the twenty-first century
Smith, M. A., Seibel, N. L., Altekruse, S. F., Ries, L. A. G., Melbert, D. L., O'Leary, M., Smith, F. O., & Reaman, G. H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0421 · Cited by 1,026 · cited 1×
“The prior COG trial design strategy incorporating cytoxic chemotherapy agents with activity in single arm phase II studies in patients with recurrent or metastatic disease has failed to generate a positive phase III trial [20,21] or to improve survival over the past 20 years in RMS [98].”
Method
Cited by
Skapek, S. X., Ferrari, A., Gupta, A. A., Lupo, P. J., Butler, E., Shipley, J., Barr, F. G., & Hawkins, D. S. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0051-2 · Cited by 875
Self-citationClassification of Rhabdomyosarcoma and Its Molecular Basis
Parham, D. M., & Barr, F. G. (2013) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3182a92d0d · Cited by 336
Characterization of mTOR Activity and Metabolic Profile in Pediatric Rhabdomyosarcoma
Felkai, L., Krencz, I., Kiss, D. J., Nagy, N., Petővári, G., Dankó, T., Micsík, T., Khoor, A., Tornóczky, T., Sápi, Z., et al. (2020) · Cancers · doi:10.3390/cancers12071947 · Cited by 13
Metadata
- Authors
- Hawkins, D. S., Spunt, S. L., Skapek, S. X., & on behalf of the COG Soft Tissue Sarcoma Committee
- Venue
- Pediatric Blood & Cancer
- Publisher
- Wiley
- Published
- 2012-12-19
- Volume
- 60
- Issue
- 6
- Pages
- 1001-1008
- ISSN
- 1545-5009 (ISSN-L)
- 1545-5017
- OpenAlex
- W2081754396
- Cited by
- 191
- References
- 2
- FWCI
- 7.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.